MAIA Biotechnology activated its first U.S. clinical site for the ongoing Phase 2 THIO-101 expansion trial of ateganosine as a third-line treatment for advanced NSCLC.
Key takeaways
Activated first U.S. site at Summit Medical Group in New Jersey for THIO-101 Phase 2 expansion trial.
Plans to open four additional U.S. sites in 2026, expanding from 44 active sites in Europe and Asia.
THIO-101 evaluates ateganosine sequenced with cemiplimab or as monotherapy in 3L NSCLC patients post-CPI and chemo failure.
U.S. third-line evaluation funded by $2.3 million NIH grant.
Holds FDA Fast Track designation for ateganosine in advanced NSCLC.
Reported OS beyond 24 months in eight patients, exceeding known 3L NSCLC benchmarks.